Unbound Prime | Pharm Unserer Zeit

(Pharm Unserer Zeit[TA])

1,431 results

[Cost-effectiveness advantage? Pharmacoeconomic aspects of biosimilars]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):485-91.Walter EPU
Publisher Full TextAggregator Full Text

["Freedom to Operate". Patent Legal Aspects in the preparation of biosimilars]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):481-4.Sommer APU
Publisher Full TextAggregator Full Text

[Similar but not identical biosimilars: the vision of innovators]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):474-80.Sydow S, Grajer KHPU
Publisher Full TextAggregator Full Text

[What is exactly alike? High-performance analytics for development of biosimilars]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):468-73.Blüggel MPU
Publisher Full TextAggregator Full Text

[Comparison of generics and original biopharmaceutical drugs. The clinical development of biosimilars]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):461-7.Brockmeyer CPU
Publisher Full TextAggregator Full Text

[When two do the same, it is not the same. Requirements for development and quality of biosimilars]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):453-60.Rais IPU
Publisher Full TextAggregator Full Text

[Molecular copies of off-patent biologics that have become biosimilars: a new group recombinant products]. [Review]
Pharm Unserer Zeit. 2012 Nov; 41(6):446-52.Dingermann T, Zündorf IPU
Publisher Full TextAggregator Full Text

[White, brown or beige rather?]. [Journal Article]
Pharm Unserer Zeit. 2012 Nov; 41(6):443-4.Zündorf I, Dingermann TPU
Publisher Full TextAggregator Full Text

[Coming soon: the pill for men?]. [Journal Article]
Pharm Unserer Zeit. 2012 Nov; 41(6):442-3.Zündorf I, Dingermann TPU

[Editorial: Pharmazie in unserer Zeit 6/2012]. [Editorial]
Pharm Unserer Zeit. 2012 Nov; 41(6):439.Dingermann TPU
Publisher Full TextAggregator Full Text

[Editorial: Pharmazie in unserer Zeit 5/2012]. [Editorial]
Pharm Unserer Zeit. 2012 Sep; 41(5):371.Steinhilber D, Schubert-Zsilavecz MPU
Publisher Full TextAggregator Full Text

[Immunotherapy with allogeneic NK cells after stem cell transplantation: harnessing a potent "killer" of tumor cells]. [Review]
Pharm Unserer Zeit. 2012 May; 41(3):239-45.Klöβ S, Köhl UPU
Publisher Full TextAggregator Full Text

[Sequelae after successful treatment of ALL in childhood and adolescence: follow-up is precautionary]. [Review]
Pharm Unserer Zeit. 2012 May; 41(3):234-8.Langer TPU
Publisher Full TextAggregator Full Text

[Infectious complications in acute lymphoblastic leukemia: Individually tailored prevention and treatment]. [Review]
Pharm Unserer Zeit. 2012 May; 41(3):228-33.Lehrnbecher T
↓1
PU
Publisher Full TextAggregator Full Text

[Stem cell transplantation for acute leukemias: Balancing risks and benefits of different treatment methods]. [Review]
Pharm Unserer Zeit. 2012 May; 41(3):222-7.Klingebiel T, Bader PPU
Publisher Full TextAggregator Full Text

Log in to Prime

Contact Support

If you need further assistance, please contact Support.

unboundmedicine.com/support
support@unboundmedicine.com
610-627-9090(Monday - Friday, 9 AM - 5 PM EST.)

Password reset sent

Username sent

A subscription to Prime is required to .

Already have an account?